Order Sucraid®
Important Safety Information
Prescribing Information
Patient Site

Could It Be CSID?

Sucraid® Treats CSID

(Congenital Sucrase- Isomaltase Deficiency)

Do you have patients suffering with unresolved IBS-like symptoms including gas, bloating, diarrhea, and/or nausea? Could it be CSID?

Download the Sucraid®
4-Day Trial Rx Form

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Do you have patients with unresolved gas, bloating, diarrhea?

Could it be CSID?

CSID is largely a clinical diagnosis. Did you rule out Celiac disease and underlying conditions and surgical procedures where CSID may not be the primary cause of symptoms?

Consider a 4-Day Trial of Sucraid® at No Cost

In a clinical trial, 81% of patients became asymptomatic* with Sucraid®.1

*Patients who took Sucraid® with each meal were considered asymptomatic if they reported no watery stools and no or mild GI symptoms (gas, bloating, nausea, vomiting, abdominal cramps) for at least 7 of the 10 study days.

  1. Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J. Sacrosidase Therapy for Congenital Sucrase-Isomaltase Deficiency. J Pediatr Gastroenterol Nutr. 1999;28(2):137-142. doi:10.1097/00005176-199902000-00008
How Sucraid® works

Sucraid®: The mechanism of action.

The active ingredient in Sucraid® is sacrosidase, which is a sucrase enzyme replacement. It splits sucrose into glucose and fructose, which facilitates absorption of both into the bloodstream from the small intestine.

Therapeutic Response Trial

Sucraid® 4-Day Trial offers eligible patients a short therapeutic trial of Sucraid® to assess response in patients clinically diagnosed with Congenital Sucrase-Isomaltase Deficiency (CSID).

Download the Sucraid®
4-Day Trial Rx Form

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Call the specialty pharmacy for information about Sucraid®

1-833-800-0122

Important Safety Information
Sucraid® (sacrosidase) Oral Solution
  • Do not prescribe Sucraid® to patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
  • Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
  • Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid®.
Indication
Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.